Clinical trials
Myositis Ossificans trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| Temporarily not available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Clementia Pharmaceuticals Inc. | 7 |
| Regeneron Pharmaceuticals | 5 |
| Ipsen | 3 |
| Incyte Corporation | 2 |
| Amsterdam UMC, location VUmc | 1 |
| Ashibio Inc | 1 |
| Daiichi Sankyo Co., Ltd. | 1 |
| Novartis Pharmaceuticals | 1 |
| The International FOP Association | 1 |
| University of California, San Francisco | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myositis Ossificans | 23 |
| Ossification, Heterotopic | 12 |
| Hallux Valgus | 2 |
| Mucopolysaccharidosis IV | 2 |
| Genetic Diseases, Inborn | 1 |
| Inflammation | 1 |
| Kidney Failure, Chronic | 1 |
| Muscular Diseases | 1 |
| Musculoskeletal Diseases | 1 |
| Myositis | 1 |
Trials
Showing 76 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.